Listed Equity: Novo Nordisk

24 Jul Listed Equity: Novo Nordisk


Novo Nordisk’s purpose is to drive the change to defeat diabetes and serious chronic diseases such as obesity, hemophilia and growth disorders. With over 95 years of experience, Novo Nordisk operates globally with innovative R&D practices, constantly implementing products through collaborative research projects with other industrial and academic partners. By discovering and developing innovative biological medicines, the company aims to make these treatments accessible to patients everywhere in the world, especially in low- and middle-income countries where cases are growing at a significant pace.

28 million patients worldwide use Novo Nordisk diabetes care products

Novo Nordisk is operating in 79 countries worldwide